<DOC>
	<DOCNO>NCT00326768</DOCNO>
	<brief_summary>The objective trial ass safety efficacy 52 week open-label treatment fix dose combination telmisartan 80 mg plus HCTZ 12.5 mg telmisartan 40 mg plus HCTZ 12.5 mg patient essential hypertension .</brief_summary>
	<brief_title>Trial Telmisartan 80 mg/HCTZ 12.5 mg Telmisartan 40 mg/HCTZ 12.5 mg Patients With Hypertension</brief_title>
	<detailed_description>This multi-centre study three centre participate target 30 90 patient enter maintenance period 20-60 patient complete long-term treatment per centre . The recruitment period three month start study . Study Hypothesis : The primary objective study demonstrate long-term safety fix dose combination telmisartan/HCTZ fixed-dose combination treatment . This study control group ; therefore , hypothesis testing perform . Comparison ( ) : This study control group .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . Essential hypertensive patient meet follow criterion : In case use antihypertensive , mean seat DBP* must 90 114 mmHg Visit 1 In case use antihypertensive , mean seat DBP* must 95 114 mmHg Visit 1 Mean seat DBP* must 90 Visit 2 ( * The mean DBP value calculate average three seated measurement take twominute interval ) . 2 . Age 20 80 year Visit 1 ( Male Female ) 3 . Outpatient 4 . Patients able stop current antihypertensive therapy Visit 1 take antihypertensive medication 5 . Patients ability provide write informed consent accordance relate law guideline Good Clinical Practice ( GCP ) Pharmaceutical Affairs Law . 1 . Patients take four antihypertensive medication Visit 1 2 . Patients know suspected secondary hypertension ( renovascular hypertension , primary aldosteronism , pheochromocytoma , etc . ) 3 . Patients whose mean seat DBP &gt; 114 mmHg and/or mean seat SBP &gt; 200 mmHg Visit 1 , Visit 2 Visit 3 4 . Patients sustain ventricular tachycardia clinically relevant cardiac arrhythmia ( AVblock IIIII , atrial fibrillation etc . ) 5 . Patients NYHA functional class heart failure IIIIV 6 . Patients history myocardial infarction cardiac surgery within last 6 3 month sign informed consent form 7 . Patients history coronary artery bypass surgery percutaneous transluminal coronary angioplasty ( PTCA ) within last 3 month sign informed consent form 8 . Patients history unstable angina within last 3 month sign informed consent form 9 . Patients hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 10 . Patients history stroke transient ischemic attack within last 6 month sign informed consent form 11 . Patients history sudden exacerbation renal function AT1 receptor antagonist ACE inhibitor ; postrenal transplant 12 . Patients previously experience characteristic symptom angioedema ( facial , tongue , pharyngeal , laryngeal swell dyspnea ) treatment AT1 receptor antagonist ACE inhibitor 13 . Patients know hypersensitivity component formulation , know hypersensitivity sulfonamide sulfonamidederived drug ( e.g . thiazide ) 14 . Known , suspected history gout</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>